收藏切换
Interpretation of the standard Specification for Safety Follow-up of Vaccine Clinical Trials (T/JPMA 023—2024)
收藏切换
Yanjun CHEN1, Hongxing PAN1, 2, Mingwei WEI1, Kangning WANG2, Qi LIANG1
Chinese Journal of Public Health | 2025, 41(11) : 1340 - 1344
Less
收藏切换
Chinese Journal of Public Health | 2025, 41(11): 1340-1344
• Special Report—Vaccine Research •
Interpretation of the standard Specification for Safety Follow-up of Vaccine Clinical Trials (T/JPMA 023—2024)
Full
Yanjun CHEN1, Hongxing PAN1, 2, Mingwei WEI1, Kangning WANG2, Qi LIANG1
Affiliations
  • 1Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention [Jiangsu Provincial Academy of Preventive Medicine], Nanjing 210009, China
  • 2School of Public Health, Nanjing Medical University, Nanjing 211166, China
Published: 2025-11-10 doi: 10.11847/zgggws1146725
Outline
收藏切换

The standard Specification for Safety Follow-up of Vaccine Clinical Trials (T/JPMA 023—2024) was published by Jiangsu Preventive Medicine Association on September 2, 2024 and officially implemented on September 9, 2024. This standard specifies the main procedures and key contents for safety follow-up after vaccination in vaccine clinical trials, and it is applicable to the follow-up of adverse events after vaccination in such trials. The safety of prophylactic vaccines is a critical focus in clinical trials and an important aspect of the vaccine registration review process. The quality of safety follow-up directly impacts the scientific validity of vaccine evaluations. This article interprets the key points of the standard and provides guidance for vaccine clinical trial institutions, trial sites, and professionals to enhance their understanding and promote the effective application of this standard.

vaccine clinical trials  /  safety follow-up  /  group standard  /  standard specification
陈彦君, 潘红星, 魏明伟, 王康宁, 梁祁. T/JPMA 023—2024《疫苗临床试验安全性随访工作规范》解读. 中国公共卫生, 2025 , 41 (11) : 1340 -1344 . DOI: 10.11847/zgggws1146725
Yanjun CHEN, Hongxing PAN, Mingwei WEI, Kangning WANG, Qi LIANG. Interpretation of the standard Specification for Safety Follow-up of Vaccine Clinical Trials (T/JPMA 023—2024)[J]. Chinese Journal of Public Health, 2025 , 41 (11) : 1340 -1344 . DOI: 10.11847/zgggws1146725
Year 2025 volume 41 Issue 11
69
30
Cite this Article
BibTeX
Article Info
doi: 10.11847/zgggws1146725
  • Receive Date:2024-12-23
  • Online Date:2026-10-25
  • Published:2025-11-10
Article Data
Affiliations
History
  • Received:2024-12-23
  • Revised:2025-05-21
  • Accepted:2025-07-24
Affiliations
    1Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention [Jiangsu Provincial Academy of Preventive Medicine], Nanjing 210009, China
    2School of Public Health, Nanjing Medical University, Nanjing 211166, China

Corresponding:

LIANG Qi, E-mail:
References
Share
https://castjournals.cast.org.cn/joweb/zgggws/EN/10.11847/zgggws1146725
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT